This invention provides a compound of the formula (I): wherein A.sup.1 is N and A.sup.2 is CR.sup.7, or A.sup.1 is CR.sup.7 and A.sup.2 is N; Y.sup.1, Y.sup.2 and Y.sup.3 are each independently CH or N, Y.sup.4 and Y.sup.5 are each independently CR.sup.8 or N, with the proviso that when one of Y.sup.1, Y.sup.2, Y.sup.3, Y.sup.4 and Y.sup.5 is N, the others are not N; R.sup.1 and R.sup.2 are each independently hydrogen, halogen, (C.sub.1-C.sub.6)alkyl, halo(C.sub.1-C.sub.6)alkyl or hydroxy(C.sub.1-C.sub.6)alkyl; R.sup.3 and R.sup.8 are each independently hydrogen, halogen, hydroxy, (C.sub.1-C.sub.6)alkyl, hydroxy(C.sub.1-C.sub.6)alkoxy, (C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkoxy, halo(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkylthio, (C.sub.1-C.sub.6)alkylsulfinyl or (C.sub.1-C.sub.6)alkylsulfonyl; R.sup.4 is halogen, (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.6)cycloalkyl, halo(C.sub.1-C.sub.6)alkyl, hydroxy(C.sub.1-C.sub.6)alkyl, halo(C.sub.1-C.sub.6)alkoxy, hydroxy(C.sub.1-C.sub.6)alkoxy, (C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkoxy, halo(C.sub.1-C.sub.6)alkylsulfonyl, halo(C.sub.1-C.sub.6)alkylsulfinyl, halo(C.sub.1-C.sub.6)alkylthio, [(C.sub.1-C.sub.6)alkyl]NH-- or [(C.sub.1-C.sub.6)alkyl].sub.2N--; and R.sup.5, R.sup.6 and R.sup.7 are each independently hydrogen, halogen, (C.sub.1-C.sub.6)alkyl, hydroxy(C.sub.1-C.sub.6)alkyl, or (C.sub.1-C.sub.6)alkoxy; or a pharmaceutically acceptable salt, solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound. ##STR00001##